AGL

Rating neutralAI Memo

agilon health

As of 2026-04-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q1 2026 results on May 6, 2026 • 2026-05-06

Base target: $28 / p=1% prob

Biggest risk

The bear case is that reverse-split optics do not change fundamentals: FY2025 adjusted EBITDA was deeply negative, membership declined, and leadership-transition risk remains visible, so another disappointing medical-margin print could reset the equity lower.

Invalidation

Break below $20 or thesis failure.

What would change my mind?

The bull case is that the reverse split clears immediate listing pressure, May 6, 2026 earnings show cleaner medical-cost performance, and management proves the FY2026 breakeven framework is achievable despite lower membership.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-18

Base target

$28

p=1%

Bull target

$38

p=0%

Bear target

$20

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Reverse-split and listing-risk overhang may fade, but only partially
FY2026 breakeven execution remains the real thesis test
The bull case is that the reverse split clears immediate listing pressure, May 6, 2026 earnings show cleaner medical-cost performance, and management proves the FY2026 breakeven framework is achievable despite lower membership.

BearKey bullets

Further membership pressure after previously disclosed market exits
Leadership-transition execution risk while the company searches for a permanent CEO
Limited margin for error if FY2026 adjusted EBITDA stays below the guided breakeven range

WatchKey bullets

Q1 2026 results on May 6, 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $28 (p=1%)

Target spread vs base: +36% / -29%

Scenario probabilities

Bull Target: $38 (p=0%)Base Target: $28 (p=1%)Bear Target: $20 (p=0%)

Commentary

The setup looks like a cautious monitoring story, not a high-conviction rebound. Primary sources confirm a completed reverse split, a near-dated May 6, 2026 earnings event, and a FY2026 plan that targets roughly breakeven adjusted EBITDA after a weak FY2025 and lower membership. That keeps sentiment neutral-to-cautious: there is a tradable event window, but the burden of proof is still on execution.

As of 2026-04-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Reverse-split and listing-risk overhang may fade, but only partially
FY2026 breakeven execution remains the real thesis test

Scenarios

Bull Target (Scenario probability)

$38 / p=0% prob

Base Target (Scenario probability)

$28 / p=1% prob

Bear Target (Scenario probability)

$20 / p=0% prob

Analysis 2026-04-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-05-06
Q1 2026 results on May 6, 2026
The company said it will report first-quarter 2026 financial results after market close on May 6, 2026, giving the market a near-term check on membership, medical margin, and whether the FY2026 path toward breakeven remains intact [#IR-2026-04-06].
Prob 90.00% • Move 18.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Reverse-split and listing-risk overhang may fade, but only partially
2026-05-31
AGL effected a 1-for-25 reverse stock split on March 30, 2026, with split-adjusted trading beginning March 31, 2026; this removes an acute price-compliance issue, but it does not fix the underlying earnings and membership pressures [#8-K-2026-03-30].
Prob 70% • Move 8% • Priced-in 75%

Long-term Catalysts

Months to a year

FY2026 breakeven execution remains the real thesis test
2026-12-31
In the FY2025 results release, agilon guided to FY2026 revenue of $5.41-$5.58 billion, medical margin of $300-$350 million, and adjusted EBITDA of negative $15 million to positive $15 million, while FY2025 platform membership had already declined to 625,000 from prior market exits; sustained execution against that framework is the main longer-duration re-rating path [#IR-2026-02-25] [#10-K-2026-02-25].
Prob 45% • Move 24% • Priced-in 30%

Risks

Further membership pressure after previously disclosed market exits
Leadership-transition execution risk while the company searches for a permanent CEO
Limited margin for error if FY2026 adjusted EBITDA stays below the guided breakeven range
Medical-cost trend or risk-adjustment underperformance versus payor assumptions
Reverse split fails to improve liquidity, sponsorship, or confidence in underlying fundamentals

Peers

Symbol	Summary
PRVA	Privia is a closer operating peer as a physician-enablement and value-based-care platform, but its official disclosures show a much larger and still-scaling network, making it a stronger execution benchmark than a valuation comp.
ASTH	Astrana is another physician-centric, risk-bearing care platform with official messaging centered on scaled value-based care enablement; versus AGL, it represents a better-executing peer in the same broad transition-to-risk ecosystem.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-18

Loading AI feed…

Symbol

Summary

PRVA

Privia is a closer operating peer as a physician-enablement and value-based-care platform, but its official disclosures show a much larger and still-scaling network, making it a stronger execution benchmark than a valuation comp.

ASTH

Astrana is another physician-centric, risk-bearing care platform with official messaging centered on scaled value-based care enablement; versus AGL, it represents a better-executing peer in the same broad transition-to-risk ecosystem.